Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus exemestane versus placebo plus exemestane in postmenopausal ER-positive advanced breast cancer refractory to non-steroidal aromatase inhibitors
NL-OMON35415Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Everolimus + exemestane with Placebo + exemestane (2 arms). Primary endpoint: Progression-free survival. Started Jul 2009; status: active, not recruiting.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON35415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35415.